cdn mobile

NBI: 1 of 5 concert casualties used drugs

Inquirer.net June 03,2016 - 09:06 AM

One of the five people who died at a concert in Pasay City two weeks ago had tested positive for two synthetic drugs, the National Bureau of Investigation (NBI) said on Thursday.

Dr. Rommel Papa, chief of staff of the NBI’s forensic division, said they found traces of methylenedioxy-methamphetamine (MDMA) methylene homolog and methylenedioxy cathinone commonly known as “bath salts.”

“Based on the autopsy report, several specimens were taken—blood, liver, brain, kidney, stomach contents—and found in the deceased body [was] the presence of methylenedioxy-methamphetamine (MDMA) methylene homolog and methylenedioxy cathinone,” Papa said, describing the two as “illicit substances.”

“It was tested and confirmed by our forensic chemistry division,” he said. “The specimens were taken by our medicolegal doctor.”

Papa refused to divulge who among the fatalities tested positive for the two illicit substances. He said the family requested the NBI not to identify the person.

MDMA methylene homolog and methylenedioxy cathinone are a new breed of drugs that the NBI’s anti-illegal drugs division has said are dangerous but not illegal. Both are not included in the list of prohibited drugs under the Dangerous Drugs Act of 2002.

MDMA methylene homolog is used for forensic tests and is not fit for human consumption.

According to Papa, the substances are classified as “psychoactive,” “mind-altering” and “hallucinogenic” drugs.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Read Next

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

TAGS: concert, drugs
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.